Clinical and immunological features of patients with atopy and concomitant HTLV-1 infection

Gaspar-Sobrinho, Fernando Pena; Souza‐Machado, Adelmir; Santos, Sara; Orge, Glória; Lessa, Hélio A.; Cruz, Álvaro Augusto; Carvalho, Edgar M.

doi:10.1590/s0100-879x2010007500138

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a high incidence in Maranhão, where 10 per 1000 blood donors are seropositive 3 . HTLV-1/2 is more frequent among women 10 in the fourth and fifth decade of life 5 , contrary to the age of the patient in this study and the data provided by CARVALHO et al (2009) 2 .…”

Section: Discussioncontrasting

confidence: 89%

Interferon Beta-1a Treatment in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Case Report

Viana

Silva

Souza

et al. 2014

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Here a young patient (< 21 years of age) with a history of infective dermatitis is described. The patient was diagnosed with myelopathy associated with HTLV-1/tropical spastic paraparesis and treated with interferon beta-1a. The disease was clinically established as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and laboratory tests confirmed the presence of antibodies to HTLV-1 in the cerebrospinal fluid (CSF). Mumps, cytomegalovirus, Epstein-Barr virus, schistosomiasis, herpes virus 1 and 2, rubella, measles, varicella-zoster toxoplasmosis, hepatitis, HIV, and syphilis were excluded by serology. The patient was diagnosed with neurogenic bladder and presented with nocturia, urinary urgency, paresthesia of the lower left limb, a marked reduction of muscle strength in the lower limbs, and a slight reduction in upper limb strength. During the fourth week of treatment with interferon beta-1a, urinary urgency and paresthesia disappeared and clinical motor skills improved.

show abstract

Section: Discussioncontrasting

confidence: 89%

Interferon Beta-1a Treatment in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Case Report

Viana

Silva

Souza

et al. 2014

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…The spontaneous cytokine levels did not differ between atopic and non-atopic HTLV-1 carriers, and these results were similar to those previously documented in the literature 13 . There is no data in the literature that compares cytokine production in atopic and non-atopic HAM/TSP patients.…”

Section: Ethical Considerationssupporting

confidence: 91%

“…Although the immune response modulation was impaired in atopic HTLV-1 carriers as these patients had lower IL-10 concentrations in cultures stimulated by Derp-1 13 , we hypothesized that the frequency at which neurological manifestations developed would be higher in atopic HTLV-1 carriers than in non-atopic HTLV-1 carriers. Our data showed no statistical difference in the incidence of Babinski signals, overactive bladders, or HAM/TSP among the groups.…”

Section: Ethical Considerationsmentioning

confidence: 99%